Stromedix Pharmaceuticals

Fibrosis therapeutics targeting the TGF-beta pathway

Stromedix was founded in 2007 to develop novel therapeutics to treat fibrosis. The company's lead asset, STX-100, is a monoclonal antibody against alpha(V)beta(6), which is involved in TGF-beta signaling. TGF-beta has linked to a number of fibrotic diseases, including idiopathic pulmonary fibrosis, and STX-100 has been shown to selectively disrupt the TGF-beta pathway. Stromedix was acquired by Biogen Idec in 2012

Acquired by Biogen Idec in 2012
Year of Investment
Life Sciences
Cambridge, Massachusetts